Academic Appointments
- Associate Professor of Psychiatry and Neurology (in the Taub Institute for Research on Alzheimer's Disease and the Aging Brain)
Edward (Ted) Huey, M.D. is an Associate Professor of Psychiatry and Neurology at Columbia University College of Physicians and Surgeons (New York, NY), in the Departments of Psychiatry (Division of Geriatric Psychiatry) and Neurology (Division of Aging and Dementia), the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, and the Gertrude H. Sergievsky Center.
Dr. Huey obtained his B.A. in psychology from Yale University. He received his medical degree from the Stanford University School of Medicine in 1999. He completed an internship and a residency in Adult Psychiatry at the Stanford University Medical Center in Stanford, California. He was elected to be the chief resident for the program in his final year of residency. He then completed a clinical research fellowship and was an Assistant Clinical Investigator in the Cognitive Neuroscience Section of the National Institute of Neurological Disorders and Stroke in the National Institutes of Health in Bethesda, MD. He was then the Director of Clinical Science of the Litwin-Zucker Research Center for the Study of Alzheimer's Disease and Memory Disorders of the Feinstein Institute, North-Shore / Long Island Jewish Medical Center. He joined the Columbia University faculty in 2010.
Dr. Huey is interested in the interface between psychiatry and neurology -- the behavioral, cognitive and emotional effects of neurological disorders and what we can learn about psychiatric disorders from patients with neuroanatomic and genetic disorders.
Dr. Huey's research has focused on patients with frontal lobe disorders, including patients with frontotemporal lobar degeneration (FTLD) and related disorders such as corticobasal syndrome and ALS, and brain injury. He studies the genetics of FTLD and is interested in the range of behavioral and emotional symptoms associated with mutations that cause FTLD. He also uses imaging in patients with frontal lobe disorders to explore the role of the frontal lobes in behavior and emotion, and the development of psychiatric disorders including mood disorders, PTSD, and OCD. A third interest is in the role of the dopamine system in the pathogenesis and treatment of the symptoms of FTLD. He is the recipient of a NIH / NINDS Pathway to Independence Award to research novel medication treatments and imaging biomarkers for FTLD.
Departments and Divisions
- Department of Psychiatry
Division of Geriatric Psychiatry - Department of Neurology
Division of Aging and Dementia
Board Certifications
- Psychiatry
Areas of Expertise
- Neuropsychiatry
- Adjustment Disorder
- Anxiety
- Attention Deficit Hyperactivity Disorder (ADHD)
- Bipolar Disorder
- Depression
- Generalized Anxiety Disorder
- Insomnia
- Mental Health
- Mood Disorders
- Obsessive Compulsive Disorder (OCD)
- Panic Disorder
- Psychopharmacology
- Psychosis
- Psychotherapy
- Social Anxiety Disorder
Education and Training
- Stanford University School of Medicine
- Residency: Stanford University Medical Center
Locations
CUIMC/Neurological Institute of New York
710 West 168th Street
New York, NY 10032
Centers / Institutes / Programs
- Taub Institute for Research on Alzheimer's Disease and the Aging Brain
Provider Affiliations
- NewYork-Presbyterian / Columbia University Irving Medical Center
Insurance Programs
Please contact the provider's office directly to verify that your particular insurance is accepted.
- AETNA [Aetna Signature Administrators, EPO, HMO, Medicare Managed Care, NYP Employee Plan, NY Signature, POS, PPO, Student Health]
- CIGNA [EPO, Great West (National), HMO, POS, PPO]
- Emblem/HIP [ConnectiCare, EPO, HMO, Medicare Managed Care, POS, PPO, Select Care (Exchange), Vytra]
- Empire Blue Cross/Blue Shield [EPO, HMO, PPO]
- Local 1199 [Local 1199]
- MagnaCare (National) [MagnaCare]
- Medicare [Railroad, Traditional Medicare]
- Oxford Health Plans [Freedom, Liberty]
- UnitedHealthcare [HMO, Medicare Managed Care, POS, PPO]
This provider accepts new patients
Appointment Phone Number: 646-426-3876
Links
Lab Locations
CUIMC/Neurological Institute of New York
710 West 168th Street
New York, NY 10032
Research Interests
- Behavioral, cognitive and emotional effects of neurological disorders
- CBD
- CBGD
- CBS
- Corticobasal ganglionic degeneration
- Corticobasal syndrome
- Frontotemporal dementia
- Frontotemporal lobar degeneration
- FTD
- FTLD
- HD
- Huntington's disease
- Neuropsychiatry
- Pick's disease
- Progressive Supranuclear Palsy
- PSP
NIH Grants
ARTFL LEFFTDS LONGITUDINAL FRONTOTEMPORAL LOBAR DEGENERATION (ALLFTD) - CLINICAL CORE (Federal Gov)
Sep 15 2019 - Jun 30 2024
ARTFL LEFFTDS LONGITUDINAL FRONTOTEMPORAL LOBAR DEGENERATION (ALLFTD) - PROJECT 1 (Federal Gov)
Sep 15 2019 - Jun 30 2024
USING RDOC NEGATIVE AND POSITIVE VALENCE PARADIGMS TO INVESTIGATE THE MECHANISMS OF NEUROPSYCHIATRIC SYMPTOMS (NPS) IN ALZHEIMER S DISEASE AND RELATED DEMENTIAS (Federal Gov)
Aug 1 2019 - May 31 2024
NEUROANATOMICAL ASSOCIATIONS WITH THE FACTOR STRUCTURE UNDERLYING NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER S DISEASE (Federal Gov)
Sep 30 2018 - May 31 2023
ANTI-VIRAL THERAPY IN ALZHEIMER S DISEASE (Federal Gov)
Sep 15 2017 - May 31 2022
PREDICTORS OF SEVERITY IN ALZHEIMER S DISEASE (Federal Gov)
Jun 15 2017 - May 31 2022
COGNITIVE TRAINING AND NEUROPLASTICITY IN MILD COGNITIVE IMPAIRMENT (Federal Gov)
Jul 15 2017 - Apr 30 2022
TASK-SPECIFIC AND PERSON-SPECIFIC FACTORS RELATED TO SUBJECTIVECOGNITIVE DECLINE (Federal Gov)
Aug 1 2017 - Apr 30 2022
IMAGINGOF COGNITION, LEARNING AND MEMORY IN AGING (Federal Gov)
May 1 2017 - Mar 31 2022
APATHY AND NEGATIVE SYMPTOMS IN ALZHEIMER S DISEASE: INVESTIGATION OF THE PROLINE*COMT INTERACTION FOR SYMPTOM TARGETING TO POSITIVELY IMPACT QUALITY OF LIFE (Federal Gov)
Sep 15 2018 - Sep 14 2021
EXPLORING COGNITIVE AGING USING REFERENCE ABILITY NEURAL NETWORKS (Federal Gov)
Aug 1 2016 - Jun 30 2021
ALZHEIMER S DISEASE RESEARCH CENTER - OVERALL (Federal Gov)
Jun 15 2015 - May 31 2021
ALZHEIMER S DISEASE RESEARCH CENTER - OVERALL (Federal Gov)
Jun 15 2015 - May 31 2021
APATHY IN ALZHEIMER S DISEASE: INVESTIGATION OF THE INTERACTION BETWEEN PROLINE AND COMT FOR TREATMENT TARGETING TO POSITIVELY IMPACT QUALITY OF LIFE (Federal Gov)
Aug 15 2018 - Apr 30 2021
THE FOUR REPEAT TAUOPATHY NEUROIMAGING INITIATIVE (Federal Gov)
Mar 1 2017 - Feb 28 2021
ARTFL LEFFTDS LONGITUDINAL FRONTOTEMPORAL LOBAR DEGENERATION (ALLFTD) - CLINICAL CORE FIXED (Federal Gov)
Sep 15 2019 - Sep 30 2020
ALZHEIMER S DISEASE RESEARCH CENTER - OVERALL (Federal Gov)
Jun 15 2015 - May 31 2020
ALZHEIMER S DISEASE RESEARCH CENTER - OVERALL (Federal Gov)
Jun 15 2015 - May 31 2020
APATHY IN ALZHEIMER S DISEASE: INVESTIGATION OF THE INTERACTION BETWEEN PROLINE AND COMT FOR TREATMENT TARGETING TO POSITIVELY IMPACT QUALITY OF LIFE (Federal Gov)
Aug 15 2018 - Apr 30 2020
EXAMINATION OF THE EARLIEST SYMPTOMS AND BIOMARKERS OF FTLD MAPT CARRIERS (Federal Gov)
Sep 21 2012 - Jul 31 2019
OLFACTORY DEFICITS AND DONEPEZIL TREATMENT IN COGNITIVELY IMPAIRED ELDERLY (Federal Gov)
Jun 15 2013 - May 31 2019
CLINICAL-PATHOLOGICAL STUDY OF COGNITIVE IMPAIRMENT IN ESSENTIAL TREMOR (Federal Gov)
Jun 1 2014 - May 31 2019
LONGITUDINAL EVALUATION OF FAMILIAL FRONTOTEMPORAL DEMENTIA SUBJECTS (LEFFTDS) (Federal Gov)
Sep 30 2014 - May 31 2019
CLINICAL-PATHOLOGICAL STUDY OF COGNITIVE IMPAIRMENT IN ESSENTIAL TREMOR (Federal Gov)
Jul 1 2015 - May 31 2019
CLINICAL-PATHOLOGICAL STUDY OF COGNITIVE IMPAIRMENT IN ESSENTIAL TREMOR (Federal Gov)
Jun 1 2014 - May 31 2019
OLFACTORY DEFICITS AND DONEPEZIL TREATMENT IN COGNITIVELY IMPAIRED ELDERLY (Federal Gov)
Jun 15 2013 - May 31 2018
OLFACTORY DEFICITS AND DONEPEZIL TREATMENT IN COGNITIVELY IMPAIRED ELDERLY (Federal Gov)
Jun 15 2013 - May 31 2018
EXAMINATION OF THE EARLIEST SYMPTOMS AND BIOMARKERS OF FTLD MAPT CARRIERS (Federal Gov)
Sep 21 2012 - Jul 31 2017
EXAMINATION OF THE EARLIEST SYMPTOMS AND BIOMARKERS OF FTLD MAPT CARRIERS (Federal Gov)
Sep 21 2012 - Jul 31 2017
LOW-DOSE LITHIUM FOR THE TREATMENT OF BEHAVIORAL SYMPTOMS IN FTD (Private)
Apr 1 2016 - Mar 31 2017
BDNF VAL66MET GENOTYPE AND AGE: IMPACT ON BIOMARKERS AND EXERCISE-BASED TREATMENT (Federal Gov)
Sep 15 2011 - May 31 2016
CLINICAL-PATHOLOGICAL STUDY OF COGNITIVE IMPAIRMENT IN ESSENTIAL TREMOR (Federal Gov)
Jul 1 2015 - May 31 2016
CLINICAL-PATHOLOGICAL STUDY OF COGNITIVE IMPAIRMENT IN ESSENTIAL TREMOR (Federal Gov)
Oct 1 2015 - May 31 2016
THE FRONTOTEMPORAL LOBAR DEGENERATION CLINICAL RESEARCH CONSORTIUM (Federal Gov)
Oct 1 2014 - Jul 31 2015
INVESTIGATION OF THE DOPAMINE SYSTEM IN FRONTOTEMPORAL DEMENTIA (Federal Gov)
May 1 2009 - Apr 30 2014
Publications
- Huey ED, Goveia EN, Paviol S, Pardini M, Krueger F, Zamboni G, Tierney MC, Wassermann EM, Grafman J: Executive dysfunction in frontotemporal dementia and corticobasal syndrome.& Neurology 2009;72(5): 453-9
- Huey ED, Pardini M, Cavanagh A, Wassermann EM, Kapogiannis D, Spina S, Ghetti B, Grafman J: Ideomotor apraxia is associated with frontal grey matter volume loss in corticobasal syndrome. Archives of Neurology 2009;66(10): 1274-80
- Koenigs M, Huey ED, Raymont V, Cheon B, Solomon J, Wassermann EM, Grafman, J: Focal brain damage protects against post-traumatic stress disorder in combat veterans. Nature Neuroscience 2008;11: 232-7
- Huey ED, Grafman J, Wassermann EM, Pietrini P, Tierney MC, Ghetti B, Spina S, Baker M, Hutton M, Elder JW, Berger SL, Heflin KA, Hardy J, Momeni P: Characteristics of frontotemporal dementia patients with a Progranulin mutation. Annals of Neurology 2006;60(3): 374-380
- Huey ED, Zahn R, Krueger F, Moll J, Kapogiannis D, Wassermann EM, Grafman J: A psychological and neuroanatomical model of obsessive-compulsive disorder. Journal of Neuropsychiatry and Clinical Neurosciences 2008;Nov: 390-408
For a complete list of publications, please visit PubMed.gov